|
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN). |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Eisai; Exelixis; Ipsen; Taiho Pharmaceutical |
Speakers' Bureau - Taiho Pharmaceutical |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); incyte (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune |
| |
|
Consulting or Advisory Role - Celgene; Eisai; Lilly |
Speakers' Bureau - Celgene; Eisai |
Research Funding - Astellas Pharma (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dynavax Technologies (Inst); EpicentRx (Inst); ERYTECH Pharma (Inst); Eureka Therapeutics (Inst); Fibrogen (Inst); Halozyme (Inst); Merck (Inst); NGM BIOPHARMACEUTICALS (Inst); OncoMed (Inst); Samumed (Inst) |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
Employment - Eisai; Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; Delcath Systems; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche |